middle.news
Argent BioPharma Cuts Costs, Posts Positive CimetrA® Trial, and Secures EU Drug Approvals
4:58am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Argent BioPharma Cuts Costs, Posts Positive CimetrA® Trial, and Secures EU Drug Approvals
4:58am on Monday 2nd of June, 2025 AEST
Key Points
Over USD $1 million annual savings by outsourcing EU GMP-certified production
Phase IIb trial confirms CimetrA®’s safety and anti-inflammatory potential
CogniCann™ receives German prescription approval and first commercial orders
CannEpil™ approved for prescription in Germany, expanding European footprint
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RGT
OPEN ARTICLE